Predictive Oncology Stock Analysis
POAI Stock | USD 0.94 0.01 1.05% |
Predictive Oncology is undervalued with Real Value of 1.45 and Target Price of 3.0. The main objective of Predictive Oncology stock analysis is to determine its intrinsic value, which is an estimate of what Predictive Oncology is worth, separate from its market price. There are two main types of Predictive Oncology's stock analysis: fundamental analysis and technical analysis.
The Predictive Oncology stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Predictive Oncology's ongoing operational relationships across important fundamental and technical indicators.
Predictive | Build AI portfolio with Predictive Stock |
Predictive Stock Analysis Notes
The company has price-to-book ratio of 1.43. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Predictive Oncology recorded a loss per share of 1.43. The entity last dividend was issued on the 29th of October 2019. The firm had 1:20 split on the 24th of April 2023. Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence primarily in the United States. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota. Predictive Oncology operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 30 people. To find out more about Predictive Oncology contact Raymond Vennare at 412 432 1500 or learn more at https://predictive-oncology.com.Predictive Oncology Investment Alerts
Predictive Oncology had very high historical volatility over the last 90 days | |
Predictive Oncology has some characteristics of a very speculative penny stock | |
Predictive Oncology has a very high chance of going through financial distress in the upcoming years | |
The company reported the previous year's revenue of 1.62 M. Net Loss for the year was (10.86 M) with profit before overhead, payroll, taxes, and interest of 880.45 K. | |
Predictive Oncology currently holds about 25.39 M in cash with (10.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.32. | |
Predictive Oncology has a frail financial position based on the latest SEC disclosures | |
Latest headline from news.google.com: Major AI Breakthrough in Cancer Research Leading Pharma Companies Unite in Revolutionary Oncology Initiative - Stock Titan |
Predictive Oncology Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Predictive Oncology previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
19th of March 2024 Upcoming Quarterly Report | View | |
31st of December 2023 Next Fiscal Quarter End | View |
Predictive Largest EPS Surprises
Earnings surprises can significantly impact Predictive Oncology's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2022-05-12 | 2022-03-31 | -0.04 | -0.05 | -0.01 | 25 | ||
2021-08-11 | 2021-06-30 | -0.07 | -0.05 | 0.02 | 28 | ||
2021-05-12 | 2021-03-31 | -0.09 | -0.11 | -0.02 | 22 |
Predictive Stock Institutional Investors
Shares | Royal Bank Of Canada | 2025-03-31 | 50.0 | Federation Des Caisses Desjardins Du Quebec | 2025-03-31 | 50.0 | Sbi Securities Co Ltd | 2025-03-31 | 5.0 | Susquehanna International Group, Llp | 2024-12-31 | 0.0 | Northern Trust Investments N A | 2024-12-31 | 0.0 | Ubs Group Ag | 2024-12-31 | 0.0 | Csenge Advisory Group, Llc | 2025-03-31 | 0.0 | Two Sigma Investments Llc | 2025-03-31 | 0.0 | Xtx Topco Ltd | 2025-03-31 | 0.0 | Vanguard Group Inc | 2025-03-31 | 71.3 K | Geode Capital Management, Llc | 2025-03-31 | 62.9 K |
Predictive Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 8.38 M.Predictive Profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (2.56) | (2.69) | |
Return On Capital Employed | (7.93) | (8.33) | |
Return On Assets | (2.45) | (2.58) | |
Return On Equity | 60.22 | 63.23 |
Management Efficiency
Predictive Oncology has return on total asset (ROA) of (0.732) % which means that it has lost $0.732 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.9037) %, meaning that it created substantial loss on money invested by shareholders. Predictive Oncology's management efficiency ratios could be used to measure how well Predictive Oncology manages its routine affairs as well as how well it operates its assets and liabilities. The Predictive Oncology's current Return On Equity is estimated to increase to 63.23, while Return On Tangible Assets are projected to decrease to (2.69). As of now, Predictive Oncology's Net Tangible Assets are increasing as compared to previous years.Last Reported | Projected for Next Year | ||
Book Value Per Share | (0.04) | (0.04) | |
Tangible Book Value Per Share | (0.08) | (0.08) | |
Enterprise Value Over EBITDA | (0.58) | (0.61) | |
Price Book Value Ratio | (22.07) | (20.97) | |
Enterprise Value Multiple | (0.58) | (0.61) | |
Price Fair Value | (22.07) | (20.97) | |
Enterprise Value | 5.9 M | 11.7 M |
Evaluating the management effectiveness of Predictive Oncology allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Predictive Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Technical Drivers
As of the 8th of June, Predictive Oncology holds the Coefficient Of Variation of (4,699), variance of 66.45, and Risk Adjusted Performance of (0.03). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Predictive Oncology, as well as the relationship between them.Predictive Oncology Price Movement Analysis
The output start index for this execution was eighteen with a total number of output elements of fourty-three. The Triple Exponential Moving Average (T3) indicator is developed by Tim Tillson as Predictive Oncology price series composite of a single exponential moving average, a double exponential moving average and a triple exponential moving average.
Predictive Oncology Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Predictive Oncology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Predictive Oncology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Predictive Oncology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Predictive Oncology Outstanding Bonds
Predictive Oncology issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Predictive Oncology uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Predictive bonds can be classified according to their maturity, which is the date when Predictive Oncology has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
MPLX LP 4125 Corp BondUS55336VAK61 | View | |
MPLX LP 52 Corp BondUS55336VAL45 | View | |
BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
MGM Resorts International Corp BondUS552953CD18 | View | |
Valero Energy Partners Corp BondUS91914JAA07 | View | |
AerCap Global Aviation Corp BondUS00773HAA59 | View |
Predictive Oncology Predictive Daily Indicators
Predictive Oncology intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Predictive Oncology stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Predictive Oncology Forecast Models
Predictive Oncology's time-series forecasting models are one of many Predictive Oncology's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Predictive Oncology's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Predictive Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Predictive Oncology prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Predictive shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Predictive Oncology. By using and applying Predictive Stock analysis, traders can create a robust methodology for identifying Predictive entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (6.69) | (7.02) | |
Operating Profit Margin | (6.74) | (7.07) | |
Net Loss | (7.51) | (7.89) | |
Gross Profit Margin | 0.49 | 0.46 |
Current Predictive Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Predictive analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Predictive analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
3.0 | Hold | 1 | Odds |
Most Predictive analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Predictive stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Predictive Oncology, talking to its executives and customers, or listening to Predictive conference calls.
Predictive Stock Analysis Indicators
Predictive Oncology stock analysis indicators help investors evaluate how Predictive Oncology stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Predictive Oncology shares will generate the highest return on investment. By understating and applying Predictive Oncology stock analysis, traders can identify Predictive Oncology position entry and exit signals to maximize returns.
Begin Period Cash Flow | 8.7 M | |
Common Stock Shares Outstanding | 5.5 M | |
Total Stockholder Equity | -202.6 K | |
Property Plant And Equipment Net | 2.4 M | |
Cash And Short Term Investments | 734.7 K | |
Cash | 734.7 K | |
Accounts Payable | 1.1 M | |
Net Debt | 1.4 M | |
50 Day M A | 1.0727 | |
Total Current Liabilities | 3.6 M | |
Other Operating Expenses | 11.7 M | |
Non Current Assets Total | 2.7 M | |
Non Currrent Assets Other | 102.5 K |
Complementary Tools for Predictive Stock analysis
When running Predictive Oncology's price analysis, check to measure Predictive Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Predictive Oncology is operating at the current time. Most of Predictive Oncology's value examination focuses on studying past and present price action to predict the probability of Predictive Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Predictive Oncology's price. Additionally, you may evaluate how the addition of Predictive Oncology to your portfolios can decrease your overall portfolio volatility.
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |